Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy has shown significant efficacy for relapsed or refractory (R/R) B-cell malignancies. Yet, CD19 CAR T cells fail to induce durable responses in most patients. Second infusions of CD19 CAR T cells (CART2) have been considered...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Gauthier, Jordan, Bezerra, Evandro D., Hirayama, Alexandre V., Fiorenza, Salvatore, Sheih, Alyssa, Chou, Cassie K., Kimble, Erik L., Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N., Jamieson, Abby W., Bar, Merav, Cassaday, Ryan D., Chapuis, Aude G., Cowan, Andrew J., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Gene Therapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7819764/
https://ncbi.nlm.nih.gov/pubmed/32967009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006770
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados